Generics in the Netherlands
SUMMARY
Generics in the Netherlands industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
SYNOPSIS
Essential resource for top-line data and analysis covering the Netherlands generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
KEY HIGHLIGHTS
For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
The market value is evaluated at ex-factory prices.
Market volume is quantified here as the percentage of the total ethical pharmaceutical market volume in a country or region which is accounted for by generic drugs. It is therefore a generics penetration rate measure, not an absolute measure of market volume.
Regional volumes are calculated as weighted averages of countries which make up the region in question where volume data exists.
Please note that any volumes of '1' (one) or 100% are due to rounding as MarketLine does not believe that generics will ever fully represent 100% of the medicinal market in any country or region.
All currency conversions were calculated at constant average annual 2016 exchange rates.
The Dutch generics market had total revenues of $1,022.4m in 2016, representing a compound annual growth rate (CAGR) of 2.1% between 2012 and 2016.
Market consumption volume increased with a CAGR of 2.7% between 2012 and 2016, to reach a total of 74.1% of total pharma volume in 2016.
Set prices and guidance from the government mean that the market will continue to grow moderately.
SCOPE
NOTE: Out of security concerns MarketLine requires using corporate email address.
SUMMARY
Generics in the Netherlands industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
SYNOPSIS
Essential resource for top-line data and analysis covering the Netherlands generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
KEY HIGHLIGHTS
For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
The market value is evaluated at ex-factory prices.
Market volume is quantified here as the percentage of the total ethical pharmaceutical market volume in a country or region which is accounted for by generic drugs. It is therefore a generics penetration rate measure, not an absolute measure of market volume.
Regional volumes are calculated as weighted averages of countries which make up the region in question where volume data exists.
Please note that any volumes of '1' (one) or 100% are due to rounding as MarketLine does not believe that generics will ever fully represent 100% of the medicinal market in any country or region.
All currency conversions were calculated at constant average annual 2016 exchange rates.
The Dutch generics market had total revenues of $1,022.4m in 2016, representing a compound annual growth rate (CAGR) of 2.1% between 2012 and 2016.
Market consumption volume increased with a CAGR of 2.7% between 2012 and 2016, to reach a total of 74.1% of total pharma volume in 2016.
Set prices and guidance from the government mean that the market will continue to grow moderately.
SCOPE
- Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in the Netherlands
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in the Netherlands
- Leading company profiles reveal details of key generics market players’ global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the Netherlands generics market with five year forecasts by both value and volume
- What was the size of the Netherlands generics market by value in 2016?
- What will be the size of the Netherlands generics market in 2021?
- What factors are affecting the strength of competition in the Netherlands generics market?
- How has the market performed over the last five years?
- How large is the Netherlands’s generics market in relation to its regional counterparts?
NOTE: Out of security concerns MarketLine requires using corporate email address.
Executive Summary
Market value
Market value forecast
Market volume
Market volume forecast
Geography segmentation
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market volume
Market Segmentation
Geography segmentation
Market Outlook
Market value forecast
Market volume forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
Mylan N.V.
Novartis AG
Sanofi SA
Teva Pharmaceutical Industries Limited
Macroeconomic Indicators
Country data
Methodology
Industry associations
Related MarketLine research
Appendix
About MarketLine
Market value
Market value forecast
Market volume
Market volume forecast
Geography segmentation
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market volume
Market Segmentation
Geography segmentation
Market Outlook
Market value forecast
Market volume forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
Mylan N.V.
Novartis AG
Sanofi SA
Teva Pharmaceutical Industries Limited
Macroeconomic Indicators
Country data
Methodology
Industry associations
Related MarketLine research
Appendix
About MarketLine
LIST OF TABLES
Table 1: Netherlands generics market value: $ million, 2012-16
Table 2: Netherlands generics market volume: % of total pharma volume, 2012-16
Table 3: Netherlands generics market geography segmentation: $ million, 2016
Table 4: Netherlands generics market value forecast: $ million, 2016-21
Table 5: Netherlands generics market volume forecast: % of total pharma volume, 2016-21
Table 6: Mylan N.V.: key facts
Table 7: Mylan N.V.: key financials ($)
Table 8: Mylan N.V.: key financial ratios
Table 9: Novartis AG: key facts
Table 10: Novartis AG: key financials ($)
Table 11: Novartis AG: key financial ratios
Table 12: Sanofi SA: key facts
Table 13: Sanofi SA: key financials ($)
Table 14: Sanofi SA: key financials (€)
Table 15: Sanofi SA: key financial ratios
Table 16: Teva Pharmaceutical Industries Limited: key facts
Table 17: Teva Pharmaceutical Industries Limited: key financials ($)
Table 18: Teva Pharmaceutical Industries Limited: key financial ratios
Table 19: Netherlands size of population (million), 2012-16
Table 20: Netherlands gdp (constant 2005 prices, $ billion), 2012-16
Table 21: Netherlands gdp (current prices, $ billion), 2012-16
Table 22: Netherlands inflation, 2012-16
Table 23: Netherlands consumer price index (absolute), 2012-16
Table 24: Netherlands exchange rate, 2012-16
Table 1: Netherlands generics market value: $ million, 2012-16
Table 2: Netherlands generics market volume: % of total pharma volume, 2012-16
Table 3: Netherlands generics market geography segmentation: $ million, 2016
Table 4: Netherlands generics market value forecast: $ million, 2016-21
Table 5: Netherlands generics market volume forecast: % of total pharma volume, 2016-21
Table 6: Mylan N.V.: key facts
Table 7: Mylan N.V.: key financials ($)
Table 8: Mylan N.V.: key financial ratios
Table 9: Novartis AG: key facts
Table 10: Novartis AG: key financials ($)
Table 11: Novartis AG: key financial ratios
Table 12: Sanofi SA: key facts
Table 13: Sanofi SA: key financials ($)
Table 14: Sanofi SA: key financials (€)
Table 15: Sanofi SA: key financial ratios
Table 16: Teva Pharmaceutical Industries Limited: key facts
Table 17: Teva Pharmaceutical Industries Limited: key financials ($)
Table 18: Teva Pharmaceutical Industries Limited: key financial ratios
Table 19: Netherlands size of population (million), 2012-16
Table 20: Netherlands gdp (constant 2005 prices, $ billion), 2012-16
Table 21: Netherlands gdp (current prices, $ billion), 2012-16
Table 22: Netherlands inflation, 2012-16
Table 23: Netherlands consumer price index (absolute), 2012-16
Table 24: Netherlands exchange rate, 2012-16
LIST OF FIGURES
Figure 1: Netherlands generics market value: $ million, 2012-16
Figure 2: Netherlands generics market volume: % of total pharma volume, 2012-16
Figure 3: Netherlands generics market geography segmentation: % share, by value, 2016
Figure 4: Netherlands generics market value forecast: $ million, 2016-21
Figure 5: Netherlands generics market volume forecast: % of total pharma volume, 2016-21
Figure 6: Forces driving competition in the generics market in the Netherlands, 2016
Figure 7: Drivers of buyer power in the generics market in the Netherlands, 2016
Figure 8: Drivers of supplier power in the generics market in the Netherlands, 2016
Figure 9: Factors influencing the likelihood of new entrants in the generics market in the Netherlands, 2016
Figure 10: Factors influencing the threat of substitutes in the generics market in the Netherlands, 2016
Figure 11: Drivers of degree of rivalry in the generics market in the Netherlands, 2016
Figure 12: Mylan N.V.: revenues & profitability
Figure 13: Mylan N.V.: assets & liabilities
Figure 14: Novartis AG: revenues & profitability
Figure 15: Novartis AG: assets & liabilities
Figure 16: Sanofi SA: revenues & profitability
Figure 17: Sanofi SA: assets & liabilities
Figure 18: Teva Pharmaceutical Industries Limited: revenues & profitability
Figure 19: Teva Pharmaceutical Industries Limited: assets & liabilities
COMPANIES MENTIONED
Mylan N.V.
Novartis AG
Sanofi SA
Teva Pharmaceutical Industries Limited
Skip to top
Figure 1: Netherlands generics market value: $ million, 2012-16
Figure 2: Netherlands generics market volume: % of total pharma volume, 2012-16
Figure 3: Netherlands generics market geography segmentation: % share, by value, 2016
Figure 4: Netherlands generics market value forecast: $ million, 2016-21
Figure 5: Netherlands generics market volume forecast: % of total pharma volume, 2016-21
Figure 6: Forces driving competition in the generics market in the Netherlands, 2016
Figure 7: Drivers of buyer power in the generics market in the Netherlands, 2016
Figure 8: Drivers of supplier power in the generics market in the Netherlands, 2016
Figure 9: Factors influencing the likelihood of new entrants in the generics market in the Netherlands, 2016
Figure 10: Factors influencing the threat of substitutes in the generics market in the Netherlands, 2016
Figure 11: Drivers of degree of rivalry in the generics market in the Netherlands, 2016
Figure 12: Mylan N.V.: revenues & profitability
Figure 13: Mylan N.V.: assets & liabilities
Figure 14: Novartis AG: revenues & profitability
Figure 15: Novartis AG: assets & liabilities
Figure 16: Sanofi SA: revenues & profitability
Figure 17: Sanofi SA: assets & liabilities
Figure 18: Teva Pharmaceutical Industries Limited: revenues & profitability
Figure 19: Teva Pharmaceutical Industries Limited: assets & liabilities
COMPANIES MENTIONED
Mylan N.V.
Novartis AG
Sanofi SA
Teva Pharmaceutical Industries Limited
Car Aftermarket Components - OES -v- Generic Suppliers Global Report
US$ 950.00
Jul, 2017 · 405 pages
